Skip Navigation

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

09 September 2022

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at the University of Colorado, Anschutz Medical Campus and ClinImmune Cell and Gene Therapy.

CorLiCyte® is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (DFU). In the study protocol nine patients with chronic DFU were treated with Corlicyte® twice weekly for 8 weeks. None of the patients participating in the study experienced any treatment-related adverse events and all subjects saw a reduction in wound size during the treatment period.

“These results are encouraging and can be used to support further research with Corlicyte® in future studies, with the potential to address unmet medical needs in treatment of patients with chronic DFUs.” said Cecilia Low-Wang, the lead investigator at the University of Colorado, Anschutz Medical Campus.

Margarida Neves, Director, Corporate Development at Adalvo comments: “We are delighted with the new Corlicyte® achievement, which proves the added value and safety of the product. These results are an important point towards our ultimate goal - globalize the product and change the lives of so many patients still searching for a solution for this unmet medical need.”